John Desmond Wade

Title: John Desmond Wade: Innovator in Relaxin Peptide Research

Introduction

John Desmond Wade is a notable inventor based in Canterbury, Australia. He has made significant contributions to the field of biochemistry, particularly in the development of relaxin peptides. With a total of 4 patents, Wade's work has implications for various therapeutic applications.

Latest Patents

Wade's latest patents include innovative formulations of biologically active single chain relaxin peptides. One of his notable inventions is related to modified relaxin B chain peptides. This invention provides biologically active single chain relaxin peptides that selectively bind to the RXFP1 receptor. The peptides are characterized by being truncated by one or more amino acid residues at the N-terminus compared to the native relaxin-2 sequence. Another significant patent involves single chain relaxin polypeptides, which are derived from relaxin-3. These polypeptides are also truncated at the C-terminus and serve as antagonists of the RXFP3 receptor, with some embodiments being selective antagonists.

Career Highlights

Throughout his career, John Desmond Wade has worked with esteemed institutions such as the Howard Florey Institute of Experimental Physiology and Medicine and the Florey Institute of Neuroscience and Mental Health. His research has contributed to advancements in understanding the role of relaxin peptides in various physiological processes.

Collaborations

Wade has collaborated with notable colleagues, including Ross Alexander David Bathgate and Mohammed Akhter Hossain. These collaborations have further enriched his research and innovation in the field.

Conclusion

John Desmond Wade's contributions to the field of relaxin peptide research highlight his innovative spirit and dedication to advancing biochemistry. His patents reflect a commitment to developing new therapeutic options that could benefit many.